Dan Li
Director/Miembro de la Junta en ZHONGCHAO INC. .
Fortuna: 2 682 $ al 30/04/2024
Perfil
Dan Li is an Independent Director at Zhongchao, Inc. since 2019.
Previously, she worked as a Manager-Medicine Management Department at EPS Holdings, Inc. from 2009 to 2011.
Dr. Li holds a doctorate degree from Keio University, a graduate degree from Peking University, and an undergraduate degree from North China University of Science & Technology.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ZHONGCHAO, INC. CLASS A
0.09% | 11/05/2023 | 1 800 ( 0.09% ) | 2 682 $ | 30/04/2024 |
Cargos activos de Dan Li
| Empresas | Cargo | Inicio |
|---|---|---|
| ZHONGCHAO INC. | Director/Miembro de la Junta | 06/08/2019 |
Antiguos cargos conocidos de Dan Li.
| Empresas | Cargo | Fin |
|---|---|---|
| EPS HOLDINGS, INC. | Corporate Officer/Principal | 01/11/2011 |
Formación de Dan Li.
| North China University of Science & Technology | Undergraduate Degree |
| Peking University | Graduate Degree |
| Keio University | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ZHONGCHAO INC. | Commercial Services |
| Empresas privadas | 1 |
|---|---|
EPS Holdings, Inc.
 EPS Holdings, Inc. BiotechnologyHealth Technology EPS Holdings, Inc. engages in the drug development business. It operates through the following segments: Contract Research Organization (CRO), Site Management Organization (SMO), Contract Sales Organization (CSO), Global Research, Ekishin, and Others. The CRO segment offers clinical trials, data management, and statistical analysis. The SMO segment enters into contracts with medical institutions to conduct clinical trials. The CSO segment provides drug information and awareness for medical and pharmaceutical industries. The Global Research segment provides consignment services through its subsidiary for multilateral clinical trials in Asia-Pacific. The Ekishin segment focuses on medical equipment, pharmaceutical and investment related businesses through its Japan and China based subsidiaries. The Others segment provides various services related to management of clinical research from business processing outsource business related to medicine and medical care. The company was founded on May 30, 1991 and is headquartered in Tokyo, Japan. | Health Technology |
- Bolsa de valores
- Insiders
- Dan Li